Form 8-K - Current report:
SEC Accession No. 0001193125-23-301812
Filing Date
2023-12-22
Accepted
2023-12-22 08:26:56
Documents
13
Period of Report
2023-12-22
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d670920d8k.htm   iXBRL 8-K 31896
2 EX-99.1 d670920dex991.htm EX-99.1 33288
  Complete submission text file 0001193125-23-301812.txt   201002

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA krtx-20231222.xsd EX-101.SCH 2842
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE krtx-20231222_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE krtx-20231222_pre.xml EX-101.PRE 11256
7 EXTRACTED XBRL INSTANCE DOCUMENT d670920d8k_htm.xml XML 3334
Mailing Address 99 HIGH STREET 26TH FLOOR BOSTON MA 02110
Business Address 99 HIGH STREET 26TH FLOOR BOSTON MA 02110 857-449-2244
Karuna Therapeutics, Inc. (Filer) CIK: 0001771917 (see all company filings)

EIN.: 270605902 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38958 | Film No.: 231507217
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)